Coya Therapeutics Inc (COYA)

$5.87 -0.09 (-1.51%)
Market Cap 122.82M
Revenue (ttm) 3.55M
Net Income (ttm) -14.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -419.15%
Debt to Equity Ratio 0.00
Volume 116,800
Avg Vol 185,720
Day's Range N/A - N/A
Shares Out 20.92M
Stochastic %K 48%
Beta 0.20
Analysts Strong Sell
Price Target $16.00

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
Jwa68
Jwa68 Nov. 14 at 8:23 PM
$COYA
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 1:19 PM
Chardan Capital has adjusted their stance on Coya Therapeutics ( $COYA ), setting the rating to Buy with a target price of 14.
0 · Reply
Apiker
Apiker Nov. 13 at 8:21 PM
$COYA added to my position! 🥳
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 6:19 PM
BTIG has adjusted their stance on Coya Therapeutics ( $COYA ), setting the rating to Buy with a target price of 15 → 16.
0 · Reply
Jwa68
Jwa68 Nov. 13 at 4:16 PM
$COYA BTIG note....Coya Therapeutics, Inc. (COYA, Buy 16.00): 3Q25 Update. Coya and low dose IL2 Could Be Significant Benefactors of EVOKE as the Inflammatory Features of AD Take Center Stage. PT to $16 from $15
0 · Reply
merlin8121
merlin8121 Nov. 13 at 11:47 AM
$COYA New report out: https://www.merlintrader.com/biotech-fury/
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 7:08 PM
D. Boral Capital has updated their rating for Coya Therapeutics ( $COYA ) to Buy with a price target of 15.
0 · Reply
Jwa68
Jwa68 Nov. 12 at 6:15 PM
$COYA Highly irrational mispriced valuation. In a fee short months, this sub $6 opportunity will hve likely aged well for those with just a tiny bit of patience. Prediction...Dr. Reddy’s buys them in Q2 of 26...$18-$24. DYDD.
0 · Reply
d_risk
d_risk Nov. 12 at 4:21 PM
$COYA - Coya Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors COYA warns that FDA and federal agency disruptions—like leadership exits, staff cuts, and policy shifts—could delay drug reviews and approvals, posing a threat to its business. #Biotechnology #Healthcare #DrugApproval #FDADelays #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/COYA/10-Q/2025-11-12
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 12 at 1:15 PM
$COYA Coya Therapeutics Q3 EPS $(0.13) Beats $(0.28) Estimate, Sales $3.564M Miss $3.700M Estimate
0 · Reply
Latest News on COYA
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 4 days ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Nov 4, 2025, 8:00 AM EST - 12 days ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 27, 2025, 4:01 PM EDT - 20 days ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Oct 24, 2025, 6:30 AM EDT - 23 days ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 23, 2025, 4:31 PM EDT - 24 days ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Oct 7, 2025, 8:00 AM EDT - 5 weeks ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 8:00 AM EDT - 6 weeks ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 8:00 AM EDT - 7 weeks ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 8:00 AM EDT - 2 months ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 4, 2025, 8:00 AM EDT - 2 months ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 11:50 AM EDT - 2 months ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sep 3, 2025, 8:34 AM EDT - 2 months ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 3 months ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 24, 2025, 8:15 AM EDT - 4 months ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jul 22, 2025, 8:15 AM EDT - 4 months ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 18, 2025, 8:15 AM EDT - 5 months ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 10:53 AM EDT - 6 months ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 6 months ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 8:15 AM EDT - 6 months ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 6 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Apr 25, 2025, 11:27 AM EDT - 7 months ago

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 7 months ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 7 months ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 8 months ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 8 months ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 8 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 9 months ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Feb 7, 2025, 5:17 PM EST - 10 months ago

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Feb 7, 2025, 1:53 PM EST - 10 months ago

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Feb 6, 2025, 1:30 PM EST - 10 months ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 10 months ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 10 months ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 10 months ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 11 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Nov 19, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Nov 1, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Oct 31, 2024, 10:31 AM EDT - 1 year ago

Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Oct 29, 2024, 2:36 PM EDT - 1 year ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:41 AM EDT - 1 year ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Coya Therapeutics Announces $10.0 Million Private Placement

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Coya Therapeutics Announces $10.0 Million Private Placement

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 13, 2024, 4:17 AM EDT - 1 year ago

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Oct 8, 2024, 9:15 AM EDT - 1 year ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Sep 24, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Jwa68
Jwa68 Nov. 14 at 8:23 PM
$COYA
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 1:19 PM
Chardan Capital has adjusted their stance on Coya Therapeutics ( $COYA ), setting the rating to Buy with a target price of 14.
0 · Reply
Apiker
Apiker Nov. 13 at 8:21 PM
$COYA added to my position! 🥳
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 6:19 PM
BTIG has adjusted their stance on Coya Therapeutics ( $COYA ), setting the rating to Buy with a target price of 15 → 16.
0 · Reply
Jwa68
Jwa68 Nov. 13 at 4:16 PM
$COYA BTIG note....Coya Therapeutics, Inc. (COYA, Buy 16.00): 3Q25 Update. Coya and low dose IL2 Could Be Significant Benefactors of EVOKE as the Inflammatory Features of AD Take Center Stage. PT to $16 from $15
0 · Reply
merlin8121
merlin8121 Nov. 13 at 11:47 AM
$COYA New report out: https://www.merlintrader.com/biotech-fury/
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 7:08 PM
D. Boral Capital has updated their rating for Coya Therapeutics ( $COYA ) to Buy with a price target of 15.
0 · Reply
Jwa68
Jwa68 Nov. 12 at 6:15 PM
$COYA Highly irrational mispriced valuation. In a fee short months, this sub $6 opportunity will hve likely aged well for those with just a tiny bit of patience. Prediction...Dr. Reddy’s buys them in Q2 of 26...$18-$24. DYDD.
0 · Reply
d_risk
d_risk Nov. 12 at 4:21 PM
$COYA - Coya Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors COYA warns that FDA and federal agency disruptions—like leadership exits, staff cuts, and policy shifts—could delay drug reviews and approvals, posing a threat to its business. #Biotechnology #Healthcare #DrugApproval #FDADelays #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/COYA/10-Q/2025-11-12
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 12 at 1:15 PM
$COYA Coya Therapeutics Q3 EPS $(0.13) Beats $(0.28) Estimate, Sales $3.564M Miss $3.700M Estimate
0 · Reply
foreverboner
foreverboner Nov. 9 at 11:22 PM
$COYA "Our"
0 · Reply
Darsh21
Darsh21 Nov. 6 at 9:17 PM
$COYA do you guys think they will hit or miss!!
3 · Reply
Robby83
Robby83 Nov. 6 at 3:45 PM
$COYA holding up well considering. Expecting the opportunity to add at the $5.50 offering price.
1 · Reply
DB32022
DB32022 Nov. 6 at 3:36 PM
$COYA the longitudinal NFL data would be nice to publish right about now
0 · Reply
Darsh21
Darsh21 Nov. 6 at 3:33 PM
$COYA what the heck is going on here!!!!
1 · Reply
Orlandotrader
Orlandotrader Nov. 5 at 9:25 PM
$COYA Waiting for 5.40 to Restart Position. Below last Offering.
1 · Reply
irf944
irf944 Nov. 5 at 7:51 PM
$COYA STock is sitting at the bottom of a Falling Wedge, whihc is a Bullish Pattern. Adding at these levels. The falling wedge pattern is a bullish chart formation in technical analysis that typically signals a potential reversal of a downtrend. It is characterized by two downward-sloping, converging trend lines that indicate a gradual loss of bearish momentum.
0 · Reply
zamped1
zamped1 Nov. 5 at 7:40 PM
$COYA taking advantage of the skunks in deal....5.70 ...20 more cents and offering....Im my opinion great risk/reward
1 · Reply
Darsh21
Darsh21 Nov. 4 at 11:48 PM
$COYA what effect will earnings have on stock price? Lately everything I have owned has tanked after earnings release and I am burnt. I want to be catious!
2 · Reply
Jwa68
Jwa68 Nov. 4 at 5:31 PM
$COYA Lakestreet note upping target to $17
0 · Reply
microcapspeculator
microcapspeculator Nov. 4 at 4:16 PM
$COYA November investor presentation on website. Runway out until 2H of 27. Plus Q4 payment upon ALS dosing. FTD next.
0 · Reply
Jwa68
Jwa68 Nov. 4 at 4:04 PM
$COYA I've repeatedly stated my belief that Dr. Reddy’s acquiring Coya is likely not a matter of if, but when and what price See the pic below from Dr. Reddy’s financials filed recently. Interesting how they refer to Coya 302 as essentially their drug. Read the first sentence...seems foretelling.
0 · Reply